Literature DB >> 30897582

Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts.

Paul G Werthmann1,2, Lothar Kindermann3, Gunver S Kienle4,5.   

Abstract

INTRODUCTION: Metastatic renal cell carcinoma has a poor prognosis. Treatment approaches with immunotherapy show promising results in subpopulations. Viscum album extracts - used as an adjunct to cancer treatment - have cytotoxic, apoptogenic, and immune-stimulating properties and show synergistic effects with chemotherapy agents. CASE REPORT: A 51-year-old man was diagnosed with metastatic renal cell carcinoma of clear cell histology which was classified as pT3a, N1, M1, G3. Nephrectomy was performed, and the patient received chemoimmunotherapy (interferon-α2a, interleukin-2, fluorouracil, isotretinoin). Additionally, he received V. album extracts as intravenous infusions and subcutaneous injections. One year after surgery, the patient was in complete remission, which is ongoing 18 years after the initial diagnosis. DISCUSSION: This case shows an extraordinarily long survival of a metastasized renal cell carcinoma patient under chemoimmunotherapy and fever-inducing V. album extracts. This combined treatment might have synergistically contributed to tumor remission and control. With regard to clinical relevance, further investigations are needed. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  13-cis-Retinoic acid; Interferon-α2a; Interleukin-2; Renal clear cell carcinoma; Viscum album

Mesh:

Substances:

Year:  2019        PMID: 30897582      PMCID: PMC6888914          DOI: 10.1159/000496866

Source DB:  PubMed          Journal:  Complement Med Res        ISSN: 2504-2092            Impact factor:   1.211


  23 in total

1.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

Authors:  R I Fisher; S A Rosenberg; G Fyfe
Journal:  Cancer J Sci Am       Date:  2000-02

Review 2.  Renal cell carcinoma.

Authors:  James J Hsieh; Mark P Purdue; Sabina Signoretti; Charles Swanton; Laurence Albiges; Manuela Schmidinger; Daniel Y Heng; James Larkin; Vincenzo Ficarra
Journal:  Nat Rev Dis Primers       Date:  2017-03-09       Impact factor: 52.329

3.  Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.

Authors:  Arie S Belldegrun; Tobias Klatte; Brian Shuch; Jeffrey C LaRochelle; David C Miller; Jonathan W Said; Stephen B Riggs; Nazy Zomorodian; Fairooz F Kabbinavar; Jean B Dekernion; Allan J Pantuck
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

4.  Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup.

Authors:  N J Vogelzang; E R Priest; L Borden
Journal:  J Urol       Date:  1992-10       Impact factor: 7.450

5.  Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

Authors:  S A Rosenberg; J C Yang; D E White; S M Steinberg
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

Review 6.  Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts.

Authors:  G S Kienle; H Kiene
Journal:  Eur J Med Res       Date:  2007-03-26       Impact factor: 2.175

Review 7.  Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.

Authors:  Gunver S Kienle; Renate Grugel; Helmut Kiene
Journal:  BMC Complement Altern Med       Date:  2011-08-28       Impact factor: 3.659

8.  Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.

Authors:  Megan L Steele; Jan Axtner; Antje Happe; Matthias Kröz; Harald Matthes; Friedemann Schad
Journal:  Evid Based Complement Alternat Med       Date:  2014-01-19       Impact factor: 2.629

9.  Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.

Authors:  Brian I Rini; David F McDermott; Hans Hammers; William Bro; Ronald M Bukowski; Bernard Faba; Jo Faba; Robert A Figlin; Thomas Hutson; Eric Jonasch; Richard W Joseph; Bradley C Leibovich; Thomas Olencki; Allan J Pantuck; David I Quinn; Virginia Seery; Martin H Voss; Christopher G Wood; Laura S Wood; Michael B Atkins
Journal:  J Immunother Cancer       Date:  2016-11-15       Impact factor: 13.751

10.  Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model.

Authors:  Carmen Steinborn; Amy Marisa Klemd; Ann-Sophie Sanchez-Campillo; Sophie Rieger; Marieke Scheffen; Barbara Sauer; Manuel Garcia-Käufer; Konrad Urech; Marie Follo; Annekathrin Ücker; Gunver Sophia Kienle; Roman Huber; Carsten Gründemann
Journal:  PLoS One       Date:  2017-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.